Researchers Identified PTK7 Role in Cancer Immune Evasion
New findings reveal how the PTK7 protein helps triple-negative breast cancer cells repair DNA damage and evade the immune system.
Updated on Oct. 10, 2026 in Cancer
Scientists discovered that the PTK7 protein translocates to the nucleus to support DNA repair, allowing triple-negative breast cancer cells to resist immune responses. This mechanism explains why high levels of PTK7 are often linked to poor responses to immunotherapy treatments.
Why it matters
By identifying this specific protein as a scaffold for DNA repair, researchers have uncovered a potential vulnerability in aggressive tumors that could improve future cancer therapies.
Research identified that PTK7 translocates to the cell nucleus to associate with DNA-PKcs, facilitating non-homologous end-joining repair. Loss of PTK7 increases double-strand breaks and activates the STING-IFN axis in tumor cells.
The players
PTK7
This protein acts as a scaffold within the cell nucleus to facilitate DNA repair mechanisms in cancer cells.
DNA-PKcs
This is a key kinase enzyme that associates with PTK7 to perform non-homologous end-joining repair of DNA double-strand breaks.
The details
The PTK7 protein functions as a critical scaffold that enhances DNA-PKcs kinase activation, directly supporting the repair of damaged DNA. When this protein is absent, the tumor experiences increased DNA damage and activates the STING-IFN axis, which subsequently increases the tumor's sensitivity to anti-PD-1 therapy.
Timeline
October 10, 2026: The research findings were published.
The Big Picture
This discovery marks a shift in our understanding of how tumors survive therapy, building upon the clinical success of the development of anti-PD-1 therapy. The findings identify a mechanism that tumor cells use to bypass immune surveillance, suggesting a new path for overcoming resistance.
This research provides a new potential target for future treatments aimed at making aggressive breast cancers more responsive to immunotherapy. Patients undergoing cancer treatment may see these findings eventually lead to new testing or combination therapies designed to bypass tumor resistance.
The takeaway
Understanding how proteins like PTK7 facilitate DNA repair offers a promising strategy to stop cancer cells from evading the immune system. Researchers believe that inhibiting this protein could turn previously resistant tumors into targets that are susceptible to standard immunotherapy.
Further reading
Learn more about the latest research in Cancer.
Source note: This article includes information reported by Nature.
